Synchroneuron Announces First Patient Dosed In Phase 2 Tardive Dyskinesia Clinical Trial
2/25/2014 9:37:50 AM
WALTHAM, Mass.--(BUSINESS WIRE)--Synchroneuron Inc., a biopharmaceutical company engaged in developing new therapies to treat tardive dyskinesia (TD) and other neuropsychiatric disorders, today announced that the first patient has been dosed in a Phase 2, multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety and pharmacokinetic behavior of orally-administered SNC-102, a new formulation of acamprosate calcium.
Help employers find you! Check out all the jobs and post your resume.
comments powered by